Veracyte, Inc.

NASDAQ:VCYT

Biotechnology

Healthcare
$25.57 +3.56%

+$1.83 today

Market cap
$2.06B
Beta
1.98
P/E (TTM)
48.0
EPS (TTM)
$1.11
52W Low $22.61High $53.66

Volume 2.45M

Average 1.05M

VCYT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Veracyte, Inc.NASDAQ: VCYT

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 72.2%

Gross margin was 72.2% in Q2 FY2026, up 3.2 pp from a year earlier. On a trailing-twelve-month basis it was 72.1%, up 3.8 pp year over year. Over 3 fiscal years it widened by 3.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
72.2%-0.1 pp QoQ
Last fiscal yearDec 2025
69.6%+2.7 pp YoY
LTMJun 2026
72.1%+3.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.2 pp——
1 year+2.7 pp——
3 years+3.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
69.6%
Year-over-year change
+2.7pp

Gross Margin vs competitors

How VCYT compares with its peers on the latest reported figures

  • VCYT's LTM Jun 2026 gross margin of 72.1% is the 3rd highest of the 10 companies compared; the peer median is 68.2%.
  • Its year-over-year change of +3.8 pp is the 2nd highest of 10, against a peer median of -0.0 pp.
  • Over three fiscal years its change of +3.9 pp compares with a peer median of +2.7 pp.
VCYT Competitors Peer median
Gross Margin for VCYT and competitors
Company Period LTM level YoY 3-year change
BDSXBiodesix, Inc.LTM Mar 202682.1% +3.7 pp+18.1 pp
CSTLCastle Biosciences, Inc.LTM Mar 202677.1% -4.9 pp+2.7 pp
VCYTVeracyte, Inc.LTM Jun 202672.1% +3.8 pp+3.9 pp
BLLNBillionToOne, Inc.LTM Jun 202671.3% +10.3 pp—
MYGNMyriad Genetics, Inc.LTM Mar 202670.0% -0.0 pp-0.3 pp
WGSGeneDx Holdings Corp.LTM Jun 202668.2% +1.0 pp+81.1 pp
GHGuardant Health, Inc.LTM Sep 202665.2% +1.4 pp-0.8 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202619.5% -33.1 pp+6.6 pp
PSNLPersonalis, Inc.LTM Mar 202613.7% -19.6 pp—
Peer median (excluding VCYT) 68.2%-0.0 pp+2.7 pp

Competitors are the stored peer set for VCYT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue219.51M296.54M361.05M445.76M517.15M
Cost of Revenue74.4M101.58M112.9M147.62M157.1M
Gross Profit145.11M194.95M248.15M298.15M360.05M
Gross Margin66.1%65.7%68.7%66.9%69.6%
Research & Development29.84M40.6M57.31M69.29M70.81M
Selling, General & Admin181.19M174.08M184.23M206.04M210.95M
Operating Expenses227.02M236.04M333.94M282M285.9M
Depreciation & Amortization19.59M25.93M27.19M23.46M21.42M
EBITDA(61.82M)(10.3M)(49.41M)49.21M89.62M
EBITDA Margin-28.2%-3.5%-13.7%11.0%17.3%
Operating Income(81.9M)(41.08M)(85.8M)16.14M74.15M
Operating Margin-37.3%-13.9%-23.8%3.6%14.3%
Interest Income135K1.97M7.34M11.15M0
Interest Expense241K198K15K2K0
Other Income / Expenses254K4.65M9.18M9.6M(5.95M)
Income Before Tax(81.65M)(36.43M)(76.61M)25.74M68.2M
Pre-Tax Margin-37.2%-12.3%-21.2%5.8%13.2%
Income Tax Expense(6.09M)133K(2.21M)1.61M1.85M
Net Income(75.56M)(36.56M)(74.4M)24.14M66.35M
Net Margin-34.4%-12.3%-20.6%5.4%12.8%
EPS (Basic)(1.11)(0.51)(1.02)0.320.84
EPS (Diluted)(1.11)(0.51)(1.02)0.310.82
Weighted Avg Shares67.89M71.55M72.64M76.48M78.58M
Weighted Avg Shares (Diluted)67.89M71.55M72.64M78.16M80.57M

Veracyte, Inc.

NASDAQ:VCYT

Intrinsic Alpha fair value

Locked

Current Price

$25.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.